Strategy & Mission
We’re developing new mechanism antibiotics to become the new standards of care
Summit Therapeutics is a leader in antibiotic innovation
We have a clear strategy: through new science and philosophy, we are creating new opportunities to become the standard of care for serious infectious diseases.
Innovation drives success in medicine. In the field of antibiotics research, no new classes of antibiotics have been approved in 15 years. With our promising pipeline and the ability of our Discuva Platform to develop future new mechanism antibiotics, we aim to change that.
Our proprietary Discuva Platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them.
In addition, ridinilazole, our Phase 3 new mechanism antibiotic for C. difficile infection (‘CDI’), is being supported by an award worth up to $72.5 million from BARDA.
We think about antibiotics differently. We design our new mechanism antibiotics to be specific for the pathogen or infection. We believe this allows us to develop antibiotics capable of meeting the unmet needs of patients and healthcare providers, show clear advantages over current therapies and create value for payors and healthcare systems. We aim to develop antibiotics for high-volume use, not to be held in reserve. Our targeted approach supports antibiotic stewardship, improved outcomes for patients and healthcare savings.
We believe our strategy creates new opportunities that are untapped in the antibiotics space. We have the potential to develop antibiotics that beat out the current standards of care and ultimately achieve commercial success. We plan to execute this strategy by becoming a fully integrated, global biopharmaceutical company. Our experienced team of scientists, clinical and regulatory developers and executives spans the drug development spectrum, from research through commercialization.
Summit Mission Statement
To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial enrollment, regulatory approval, and commercializing patient-, physician-, caregiver-, payor-, and societal-friendly medicinal therapy* intended to improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to pursue commercialization and/or development partners when and where appropriate. Our initial area of accomplishment is to be infectious disease and specifically Clostridioides difficile.
We will accomplish this by building a team of world class scientists and business administrators that apply themselves to this mission. Team Summit exists to strategize and execute a path forward in medicinal therapeutic health care that places us in a top market share leadership position. Team Summit assumes responsibility for stimulating continuous expansion of knowledge, ability, capability, and wealth for all involved stakeholders.
*For our purposes, friendly medicinal therapy is defined as follows: therapeutic efficacy (cure with duration and without recurrence and resistance) over therapeutic trauma. Therapeutic trauma is defined as serious side effects while on therapy or post-therapy but related to therapy, disease recurrence, patient non–compliance with daily dosage due to challenges associated with our therapy, its unaffordability, or inaccessibility.
Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Cambridge, Massachusetts, and we have offices in Oxford, UK, and Cambridge, UK.